Photocure fundamentale forhold (PHO)

[TekBot]

Photocure ASA: Results for the third quarter of 2021

Oslo, Norway, 17 November 2021: Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 86.7 million in the third quarter of 2021
(Q3 2020: NOK 49.6), and EBITDA of NOK -0.2 million (-5.4), following the
…

Vis børsmeldingen

continued successful launch in markets previously operated by Ipsen Pharma SAS.
The Company plans to increase its investment in commercial activities to further
penetrate the large potential market opportunity for its bladder cancer
treatment.

“Photocure continued to grow its business during the third quarter of 2021,
despite the challenges that arose from the surge of Covid-19 Delta which
impacted medical procedures around the world. We delivered Hexvix/Cysview
revenue of NOK 86.7 million, up 75% compared to the third quarter of 2020. These
results were primarily driven by our reacquisition of the Hexvix business in
continental Europe and our focus on territories where healthcare access improved
in the third quarter. Importantly, demand for blue light cystoscopy (BLC)
equipment remains strong with 14 towers placed in the U.S. in Q3. We remain
conservative on the number of towers that we expect to place over the next
couple of quarters, given Karl Storz’s planned transition to a new high
-definition system in 2022. We believe that launch of the upgraded BLC system is
an exciting opportunity with the potential to significantly increase the
installed base of BLC towers in the U.S. next year and beyond,” said Daniel
Schneider, President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 87.4 million in the third quarter
of 2021 (NOK 49.9 million), and EBITDA* of NOK -0.2 million (NOK -5.4 million).
Hexvix/Cysview revenues were NOK 86.7 million (NOK 49.6 million) following the
successful transition of the Ipsen territories and unit sales growth of 6% in
the U.S. EBIT ended at NOK -6.3 million (-16.4) and the cash balance at the end
of third quarter 2021 was NOK 330.1 million, compared to NOK 321.8 million
reported in the third quarter of 2020.

The installed base of blue light cystoscopes in the U.S. was 302 at the end of
the third quarter, an increase of 49 units or 19% since the same period in 2020.
BLC with Cysview in the surveillance setting is a priority for Photocure in the
U.S. market. By the end of the third quarter, a total base of 45 flexible
cystoscopes had been installed giving more patients access to the procedure with
less constraints.

“We continue to maintain a strong financial position with NOK 330 million in
cash and minimal debt. We reported break-even EBITDA in the third quarter, as we
continue to manage through what appears to be the tail end of the pandemic and
have begun to invest more aggressively in initiatives to regain growth in our
direct markets. We also reacquired the commercial rights to Cysview in Canada
and are preparing to begin growing that business in January,” Schneider added.

After regaining sales and marketing rights to the European markets that were
previously out-licensed, the Company has established a strong commercial
presence in the largest markets of the world and believes that it is well
-positioned to accelerate revenues in a post Covid-19 environment. Assuming that
the effects of Covid-19 and its variants can be appropriately managed, Photocure
plans to increase spending back to normalized business levels in the fourth
quarter of 2021, increasing investment primarily in commercial activities to
grow Hexvix/Cysview unit sales.

“We are optimistic that the challenging conditions of the pandemic that have
persisted for nearly two years will improve going forward. Our teams are
energized to deliver patient value and revenue growth in 2022, with the
expectation of new enhanced BLC equipment and focus from Karl Storz, expansion
of our business into Canada, the ability of our strengthened European commercial
team to have broader access to our new customers and territories, the potential
to execute on enriching our portfolio through partnerships or M&A opportunities,
and anticipated progress on the ongoing Phase 3 trial for Cevira. With the
impact of Covid-19 expected to abate in H1 2022, Photocure remains in a strong
position to get back to the growth rates that we were delivering pre-pandemic,
and to capitalize on other opportunities that can enhance our growth and path
toward sustainable profitability,” Schneider concluded.

Please find the full financial report and presentation enclosed.

*EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
third quarter 2021 financial report on page 25.

Photocure will present its third quarter 2021 report on Wednesday 17 November
2021 at 14:00 CET. The investor presentation will be streamed live and be hosted
by Daniel Schneider, CEO and Erik Dahl, CFO.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20211117_5/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 17 November 2021 at 07:30 CET.

Kilde

[E24Bot]

Photocure øker inntektene, men preges av coronausikkerhet

Photocure øker inntektene, men preges av coronausikkerhet

[Savepig]

Det er ingen jubelrapport helt åpenbart, men godt å se at basen av rigide skop fortsetter å stige.

Flex skop har ikke blitt det vi håpet enda, og revenue utvikling er svak ift hva man hadde håpt.

[Ekspertis1]

Enig der. Men jeg forholder meg fortsatt positiv på sikt. Schneider sa også tydelig ifra ved Q2 rapporten at Q3 ikke ble noe å glede seg til resultatmessig. Derfor bør dette kvartalet være noe absolutt alle forventet

[Hayen]

[rosk82]

Hvis man ser litt lenger en akkurat i dag, så ser man veksten er der.

2019, som var det året Photocure produserte den høyeste omsetningen før Covid traff, var man på 166mil ved Q3. I dag er man på 266mil.

Ser man på hele 2019 og 2020, kom man inn på henholdsvis 281mil og 256mil.

Hele 2020 har man allerede passert med 10mil, dette er inkludert 4% tap pga. ugunstig valuta utslag og fremdeles utfordring med tilgang med tanke på Covid.

2019 ligger man kun ca 15mil bak, men med et helt kvartal igjen.

Uten videre vekst vil Photocure passere 350 mil ved Q4. I tillegg venter vi på nytt ifra Asieris med tanke på Cevira og Cysview.

Og med tanke på hva Photocure klarte å få ut av Europa etter å ha tatt dette tilbake, kan man jo begynne å tenke vekst i Canada også.

[Hayen]

@rosk82

ugunstig valuta utslag

Ved samme valutakurs USD i 2021 som i 2020, ville omsetningen i USA vært ca 9,3 mill høyere i år( beregnet av meg mot månedlig USD kurs Norges Bank)

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (105 likes)

@Rodjer

Ny klinikk oppført på Cysview.

2. @Savepig (52 likes)

@Savepig

Dette er så offtopic at jeg får lyst til å ramme det inn og henge i nasjonalgalleriet

3. @OYV (43 likes)

@OYV

https://twitter.com/randerkrans/status/1445441172332290050?s=21

Resten av topp 10:

4. @rosk82 (43 likes)

5. @myk (40 likes)

6. @togulle (37 likes)

7. @h3nk1 (33 likes)

8. @TyrionIV (31 likes)

9. @Hayen (27 likes)

10. @Meisen (26 likes)

Gratulerer!

[TekBot]

Major shareholder disclosure in Photocure ASA

Please see attachment on www.newsweb.no
…

Vis børsmeldingen

Kilde

[TheLion]

[TekBot]

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 3 December 2021: Participants in Photocure ASA’s (“Photocure” or
the “Company”) share option program have on 3 December 2021 exercised a total of
30 000 options distributed as follows:
…

Vis børsmeldingen

· 1500 options exercised according to the option program for 2019 at a strike
price of NOK 50.72; and
· 28 500 options exercised according to the option program for 2019 at a
strike price of NOK 81.41.

Each option gives a right to receive one share in the Company. The share options
are described in note 7 and 23 in Photocure’s annual financial statements for
2020.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company’s Annual General Meeting, has decided to increase the
Company’s share capital by NOK 15 000 by issuing 30 000 new shares, of par value
NOK 0.50. Subsequent to the transaction, Photocure’s share capital will be NOK
13 486 910 divided into 26 973 820 shares, each share having a par value of NOK
0.50 and carrying one vote in the Company’s general meeting.

The following options are exercised by primary insider:

· 22 500 options are exercised by primary insider of the Company Susanne
Strauss, VP and General Manager of Europe

Primary insider notifications pursuant to the market abuse regulation article 19
is attached.

The primary insiders mentioned above has transferred their rights to receive
shares resulting from the exercise of options to a third party. Following a sale
of shares, the primary insiders will receive the net proceeds after deduction of
the strike price and accrued tax. The primary insiders will use the full net
proceeds to purchase shares in Photocure. The sales amount and the number of
shares purchased will be finally determined on the basis of the price
subsequently obtained by the third party in the market. The results of the sales
process will be announced in a separate stock exchange notice when known.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

[TekBot]

Photocure ASA: Exercise of employee share options

Oslo, Norway, 6 December 2021: Reference is made to the stock exchange release
by Photocure ASA (“Photocure” or the “Company”) published on 3 December 2021
regarding exercise of share options.
…

Vis børsmeldingen

The price for option shares sold by the primary insider, Susanne Strauss, VP and
General Manager of Europe, has been determined at a price of NOK 94.2502 per
share.

The primary insider having exercised options has used the net proceeds from the
sale of option shares to purchase 1,392 shares in Photocure at a price per share
of NOK 94.2502.

Primary insider notification pursuant to the market abuse regulation article 19
is attached.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

[TekBot]

Photocure ASA: Share capital increase registered

Oslo, Norway, 9 December 2021: Reference is made to the stock exchange release
by Photocure ASA (“Photocure” or the “Company”) published on 3 December 2021
regarding a share capital increase following the exercise of share options.
…

Vis børsmeldingen

The issuance of 30,000 new shares has been registered with the Norwegian
Register of Business Enterprises. Following registration, the share capital of
Photocure is NOK 13,486,910 divided into 26,973,820 shares, each share having a
par value of NOK 0.50 and carrying one vote in the Company’s general meeting.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA Photocure:
The Bladder Cancer Company delivers transformative solutions to improve the
lives of bladder cancer patients. Our unique technology, making cancer cells
glow bright pink, has led to better health outcomes for patients worldwide.
Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (OSE: PHO). For more information, please visit us at www.photocure.com,
www.hexvix.com or www.cysview.com All trademarks mentioned in this release are
protected by law and are registered trademarks of Photocure ASA. This
information is subject to the disclosure requirements pursuant to sections 5-12
of the Norwegian Securities Trading Act.

Kilde

[CanonBoy]

Cevira fase3/Apricity Phase 3.

Denne ble publisert 2. Desember og gir god informasjon om selve studien og litt om status pr november.

A multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira®) as a novel treatment in patients with high grade squamous intraepithelial lesion: APRICITY Phase 3 study protocol

Results
APRICITY Phase 3 study of Cevira® is currently recruiting patients in Europe and China. Recruitment started in November 2020 with the aim to enrol at least 384 patients over the period of 15 months. Planned overall duration of the study is 34 months, with last patient last visit planned in September 2023.

As of November 12, 2021, 188 patients have been enrolled in China and 6 patients in Europe, with 60% and 40% of patients being diagnosed with CIN2 with CIN3, respectively. HPV status of the enrolled patients: HPV- (3%), HPV16+ (59%) and HPV18+Other+ (38%). The majority of patients was aged 21-40 years (93%), with 1% of younger women (age group 18- 20 years) and 4.3% of women over 40 years of age.

As of 1st of November 2021, 54 sites have been initiated with 45 sites in China, 3 in Hungary, 2 in Ukraine, 2 in Germany and 2 site in Slovakia. In total, 194 patients have been enrolled.

Link:
https://www.researchgate.net/publication/356828343_A_multicentre_prospective_randomised_controlled_trial_to_evaluate_hexaminolevulinate_photodynamic_therapy_CeviraR_as_a_novel_treatment_in_patients_with_high_grade_squamous_intraepithelial_lesion_APRIC

Som PDF:

A-multicentre-prospective-randomised-controlled-trial-to-evaluate-hexaminolevulinate-photodynamic-therapy-CeviraR-as-a-novel-treatment-in-patients-with-high-grade-squamous-intraepithelial-lesion-APR.pdf

[OYV]

Tusen takk for god graving og deling. Noen med større innsikt enn meg som mener noe om rekrutteringstakten? Og; skal det finne sted noen form for avlesning av resultater før alle pasienter er behandlet?

[HO5]

384 pasienter over 15 mnd skulle tilsi en takt på 25,6 pr mnd.

På 12, 5 mnd har de 194, som viser en takt på 15,5

Vet ikke om studiet stiller krav til fordeling av pasienter på de ulike regionene.

Lugger en del på rekrutteringen her også, som i alt annet.

[Fso]

Var det ikke ved sidste patient indrullet at der kom en slat penge?
Dvs med nuværende hastighed q3 eller q4 2022 sku der ha stået

[Hayen]

Tror du må regne på nytt.
De ligger an til å være ferdig med rekruttering rundt årsskiftet 2022/2023.

Samtidig er det naturlig å anta at rekrutteringen var tregere i starten enn det er nå. Jeg ser også at stadig flere klinikker/sykehus inkluderes i studien

[Fso]

Har rettet i det ovenstående.
Med 15,5 pr mdr og der mangler 180. Så siger vi ca 12 mdr fra den 1/11-2021.
Som du er inde på vil rekrutterings takten nok tage sig op så lad os se om ik det blir i Q3 2022.

[yrune]

Ikke ferdig rekruttert, slik jeg forstår det skriver de jo at de hadde planer om å få inn minst 384 pasienter de første 15mnd, dog skulle de holde på i 34 mnd etter planen. Så de skal vel ha inn mange flere pasienter enn 384. DVS `minst ca 900 totalt ?